Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The transcript referred to as "novel transcript, antisense to NCK2" (ENSG00000290119) is a natural antisense long non-coding RNA that overlaps the NCK2 gene in the human genome. NATs are a widespread class of regulatory RNA molecules that can interact with their 'sense' counterpart genes through several mechanisms, including transcriptional interference, RNA masking, and recruitment of epigenetic modifiers[1][2][3][4]. These processes can modulate gene expression, alternative splicing, mRNA stability, and chromatin state, impacting biological regulation. However, there is no published functional or disease association specific to ENSG00000290119, nor is it recognized as a druggable target or biomarker. NATs are an active area of research for understanding gene regulation, but many remain uncharacterized with respect to direct molecular or disease relevance.
None known for drugs; hypothetical mechanisms could include RNA interference or antisense oligonucleotide-mediated degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to NCK2 (ENSG00000290119).